SCHEMBL10136925

SCHEMBL10136925

CC(=O)NCCN1CCC(CCCN2c3ccccc3Sc3ccc(C)cc32)CC1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DRD3 P35462 6/20 0.60
HRH1 P35367 6/20 0.60
SLC6A2 P23975 5/20 0.60
DRD2 P14416 5/20 0.60
HTR1A P08908 4/20 0.60
ADRA1A P35348 4/20 0.60
SLC6A3 Q01959 4/20 0.60
KCNH2 Q12809 4/20 0.60
SLC6A4 P31645 4/20 0.60
CHRM2 P08172 3/20 0.60
CHRM1 P11229 3/20 0.60
ADRA2B P18089 3/20 0.60
ADRA2C P18825 3/20 0.60
HTR2A P28223 3/20 0.60
HTR2B P41595 3/20 0.60
CYP2D6 P10635 2/20 0.60
HTR2C P28335 2/20 0.60
MEN1 O00255 2/20 0.60
KMT2A Q03164 2/20 0.60
USP2 O75604 1/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10136909 0.90 DRD3 (0.55) DRD3HRH1SLC6A2DRD2HTR1A
SCHEMBL10136857 0.89 KDM1A (0.61) DRD3HRH1SLC6A2DRD2HTR1A
SCHEMBL10168005 0.89 FPR2 (0.64) DRD3HRH1SLC6A2DRD2HTR1A
SCHEMBL10136910 0.84 DRD3 (0.56) DRD3HRH1SLC6A2DRD2HTR1A
SCHEMBL10136921 0.83 DRD3 (0.58) DRD3HRH1SLC6A2DRD2HTR1A
SCHEMBL10136952 0.82 HTR1A (0.56) DRD3HRH1SLC6A2DRD2HTR1A
SCHEMBL15908329 0.82 HTR1A (0.52) DRD3HRH1SLC6A2DRD2HTR1A
SCHEMBL20425963 0.82 DRD3 (0.72) DRD3HRH1SLC6A2DRD2HTR1A
SCHEMBL10136955 0.80 DRD2 (0.55) DRD3HRH1SLC6A2DRD2HTR1A
SCHEMBL10168008 0.79 FPR2 (0.61) DRD3HRH1SLC6A2DRD2HTR1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120035161-A1 Novel Compositions and Methods of Treating Diseases Using the Same CORRIDOR PHARMACEUTICALS, INC. 2012-02-09 US disclosed
US-7923445-B2 10-{3-[4-(2-Amino)ethylpiperazinyl]propyl}2-trifluoromethylphenothiazine and analogues and derivatives; antiproliferative agents; serotonin receptor antagonists; apoptosis in activated lymphocytes, including T, B, and and mylenoma cells; asthma; antiarthritic agents; rheumatic diseeases IMMUNE CONTROL, INC. (US) 2011-04-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120035161-A1 Novel Compositions and Methods of Treating Diseases Using the Same NFATC1, BAX, BCL2 DRD3 4778/4885HRH1 1212/4885SLC6A2 4623/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.